Gut-directed hypnotherapy significantly augments clinical remission in quiescent ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 7, 2013, Pages 761-771

  Keefer, L ^a,b   Taft, T H ^a,b   Kiebles, J L ^c   Martinovich, Z ^a   Barrett, T A ^a   Palsson, O S ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c HINES VA HOSPITAL   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ATTENTION; BEHAVIOR CONTROL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GUT DIRECTED HYPNOTHERAPY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MENTAL STRESS; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADULT; COLITIS, ULCERATIVE; FEASIBILITY STUDIES; FEMALE; HUMANS; HYPNOSIS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84883484059     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12449     Document Type: Article

References (73)

1. Loftus CG, Loftus EV Jr, Harmsen WS, et al,. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007; 13: 254-61.
2. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al,. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007; 5: 1424-9.
3. Waljee AK, Joyce JC, Wren PA, Khan TM, Higgins PD,. Patient reported symptoms during an ulcerative colitis flare: a Qualitative Focus Group Study. Eur J Gastroenterol Hepatol 2009; 21: 558-64.
4. Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al,. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 2012; 61: 241-7.
5. Achleitner U, Coenen M, Colombel JF, Peyrin-Biroulet L, Sahakyan N, Cieza A,. Identification of areas of functioning and disability addressed in inflammatory bowel disease-specific patient reported outcome measures. J Crohns Colitis 2012; 6: 507-17.
6. Abraham BP, Sellin JH,. Disability in inflammatory bowel disease. Gastroenterol Clin North Am 2012; 41: 429-41.
7. Reinisch W, Sandborn WJ, Bala M, et al,. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis 2007; 13: 1135-40.
8. Bernstein CN, Singh S, Graff LA, Walker JR, Miller N, Cheang M,. A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol 2010; 105: 1994-2002.
9. Walker JR, Ediger JP, Graff LA, et al,. The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am J Gastroenterol 2008; 103: 1989-97.
10. Keefer L, Keshavarzian A, Mutlu E,. Reconsidering the methodology of "stress" research in inflammatory bowel disease. J Crohns Colitis 2008; 2: 193-201.
11. Maunder RG, Levenstein S,. The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence. Curr Mol Med 2008; 8: 247-52.
12. Rogala L, Miller N, Graff LA, et al,. Population-based controlled study of social support, self-perceived stress, activity and work issues, and access to health care in inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 526-35.
13. Graff LA, Walker JR, Clara I, et al,. Stress coping, distress, and health perceptions in inflammatory bowel disease and community controls. Am J Gastroenterol 2009; 104: 2959-69.
14. von Wietersheim J, Kessler H,. Psychotherapy with chronic inflammatory bowel disease patients: a review. Inflamm Bowel Dis 2006; 12: 1175-84.
15. Jensen MP, Gralow JR, Braden A, Gertz KJ, Fann JR, Syrjala KL,. Hypnosis for symptom management in women with breast cancer: a pilot study. Int J Clin Exp Hypn 2012; 60: 135-59.
16. Hudacek KD,. A review of the effects of hypnosis on the immune system in breast cancer patients: a brief communication. Int J Clin Exp Hypn 2007; 55: 411-25.
17. Sohl SJ, Stossel L, Schnur JB, Tatrow K, Gherman A, Montgomery GH,. Intentions to use hypnosis to control the side effects of cancer and its treatment. Am J Clin Hypn 2010; 53: 93-100.
18. Horton-Hausknecht JR, Mitzdorf U, Melchart D,. The effect of hypnosis therapy on the symptoms and disease activity in rheumatoid arthritis. Psychol Health 2000; 14: 1089-104.
19. Rucklidge JJ, Saunders D,. The efficacy of hypnosis in the treatment of pruritus in people with HIV/AIDS: a time- series analysis. Int J Clin Exp Hypn 2002; 50: 149-69.
20. Langenfeld MC, Cipani E, Borckardt JJ,. Hypnosis for the control of HIV/AIDS-related pain. Int J Clin Exp Hypn 2002; 50: 170-88.
21. Bernardy K, Fuber N, Klose P, Hauser W,. Efficacy of hypnosis/guided imagery in fibromyalgia syndrome-a systematic review and meta-analysis of controlled trials. BMC Musculoskelet Disord 2011; 12: 133.
22. Alvarez-Nemegyei J, Negreros-Castillo A, Nuno-Gutierrez BL, Alvarez-Berzunza J, Alcocer-Martinez LM,. Ericksonian hypnosis in women with fibromyalgia syndrome. Rev Med Inst Mex Seguro Soc 2007; 45: 395-401.
23. Tan G, Fukui T, Jensen MP, Thornby J, Waldman KL,. Hypnosis treatment for chronic low back pain. Int J Clin Exp Hypn 2010; 58: 53-68.
24. Jensen MP,. Hypnosis for chronic pain management: a new hope. Pain 2009; 146: 235-7.
25. Wood GJ, Bughi S, Morrison J, Tanavoli S, Zadeh HH,. Hypnosis, differential expression of cytokines by T-cell subsets, and the hypothalamo-pituitary-adrenal axis. Am J Clin Hypn 2003; 45: 179-96.
26. Miller GE, Cohen S,. Psychological interventions and the immune system: a meta-analytic review and critique. Health Psychol 2001; 20: 47-63.
27. Montgomery GH, Bovbjerg DH, Schnur JB, et al,. A randomized clinical trial of a brief hypnosis intervention to control side effects in breast surgery patients. J Natl Cancer Inst 2007; 99: 1304-12.
28. Nash MR, Tasso A,. The effectiveness of hypnosis in reducing pain and suffering among women with metastatic breast cancer and among women with temporomandibular disorder. Int J Clin Exp Hypn 2010; 58: 497-504.
29. Lynch DF Jr,. Empowering the patient: hypnosis in the management of cancer, surgical disease and chronic pain. Am J Clin Hypn 1999; 42: 122-30.
30. Ginandes C, Brooks P, Sando W, Jones C, Aker J,. Can medical hypnosis accelerate post-surgical wound healing? Results of a clinical trial. Am J Clin Hypn 2003; 45: 333-51.
31. Kiecolt-Glaser H, Marucha PT, Atkinson C, Glaser R,. Hypnosis as a modulator of cellular immune dysregulation during acute stress. J Consult Clin Psychol 2001; 69: 674-82.
32. Kiecolt-Glaser JK, Glaser R, Strain EC, et al,. Modulation of cellular immunity in medical students. J Behav Med 1986; 9: 5-21.
33. Palsson OS,. Hypnosis treatment for gut problems. Eur Gastroenterol Hepatol Rev 2010; 6: 42-6.
34. Tan G, Hammond DC, Joseph G,. Hypnosis and irritable bowel syndrome: a review of efficacy and mechanism of action. Am J Clin Hypn 2005; 47: 161-78.
35. Whitehead WE,. Hypnosis for irritable bowel syndrome: the empirical evidence of therapeutic effects. Int J Clin Exp Hypn 2006; 54: 7-20.
36. Palsson OS, Turner MJ, Johnson DA, Burnett CK, Whitehead WE,. Hypnosis treatment for severe irritable bowel syndrome: investigation of mechanism and effects on symptoms. Dig Dis Sci 2002; 47: 2605-14.
37. Calvert EL, Houghton LA, Cooper P, Morris J, Whorwell PJ,. Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 2002; 123: 1778-85.
38. Sharma RL,. Functional dyspepsia: at least recommend hypnotherapy. BMJ 2008; 337: a1972.
39. Palsson OS, Whitehead WE,. Hypnosis for non-cardiac chest pain. Gut 2006; 55: 1381-4.
40. Chiarioni G, Vantini I, De Iorio F, Benini L,. Prokinetic effect of gut-oriented hypnosis on gastric emptying. Aliment Pharmacol Ther 2006; 23: 1241-9.
41. Sobala GM, Poynton A, Colgan SM, Faragher EB, Whorwell PJ., Hypnotherapy for duodenal ulcer. Lancet 1988; 2: 159-60.
42. Shaoul R, Sukhotnik I, Mogilner J,. Hypnosis as an adjuvant treatment for children with inflammatory bowel disease. J Dev Behav Pediatr 2009; 30: 268.
43. Miller V, Whorwell PJ,. Treatment of inflammatory bowel disease: a role for hypnotherapy? Int J Clin Exp Hypn 2008; 56: 306-17.
44. Emami MH, Gholamrezaei A, Daneshgar H,. Hypnotherapy as an adjuvant for the management of inflammatory bowel disease: a case report. Am J Clin Hypn 2009; 51: 255-62.
45. Keefer L, Keshavarzian A,. Feasibility and acceptability of gut-directed hypnosis on inflammatory bowel disease: a brief communication. Int J Clin Exp Hypn 2007; 55: 457-66.
46. Mawdsley JE, Jenkins DG, Macey MG, Langmead L, Rampton DS,. The effect of hypnosis on systemic and rectal mucosal measures of inflammation in ulcerative colitis. Am J Gastroenterol 2008; 103: 1460-9.
47. Keefer L, Kiebles JL, Kwiatek MA, et al,. The potential role of a self-management intervention for ulcerative colitis: a brief report from the ulcerative colitis hypnotherapy trial. Biol Res Nurs 2012; 14: 71-7.
48. Hammond DC, Scheflin AW, Vermetten E,. Informed consent and the standard of care in the practice of clinical hypnosis. Am J Clin Hypn 2001; 43: 305-10.
49. Keefer L, Kiebles JL, Martinovich Z, Cohen E, Van Denburg A, Barrett TA,. Behavioral interventions may prolong remission in patients with inflammatory bowel disease. Behav Res Ther 2011; 49: 145-50.
50. Munder T, Gerger H, Trelle S, Barth J,. Testing the allegiance bias hypothesis: a meta-analysis. Psychother Res 2011; 21: 670-84.
51. Higgins P, Schwartz M, Mapili J, Zimmerman EM,. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol 2005; 100: 355-61.
52. Irvine EJ,. Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality- of-life instrument for adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1999; 28: S23-7.
53. Morisky D, Green LW, Levine DM,. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67-74.
54. Keefer L, Kiebles JL, Taft TH,. The role of self-efficacy in inflammatory bowel disease management: preliminary validation of a disease-specific measure. Inflamm Bowel Dis 2011; 17: 614-20.
55. Levenstein S, Prantera C, Varvo V, et al,. Development of the perceived stress questionnaire: a new tool for psychosomatic research. J Psychosom Res 1993; 37: 19-32.
56. Levenstein S, Prantera C, Varvo V, et al,. Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am J Gastroenterol 2000; 95: 1213-9.
57. Ware JE, Kosinski M, Turner-Bowker DM, Gandek B,. Version 2 of the SF-12 Health Survey. Lincoln, RI: QualityMetric Incorporated, 2002.
58. Ware JE,. SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center, 1993.
59. Higgins PD, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM,. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005; 54: 782-8.
60. Weizman AV, Ahn E, Thanabalan R, et al,. Characterisation of complementary and alternative medicine use and its impact on medication adherence in inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 342-9.
61. Lindfors P, Unge P, Nyhlin H, et al,. Long-term effects of hypnotherapy in patients with refractory irritable bowel syndrome. Scand J Gastroenterol 2012; 47: 414-20.
62. Gonsalkorale WM, Miller V, Afzal A, Whorwell PJ,. Long term benefits of hypnotherapy for irritable bowel syndrome. Gut 2003; 52: 1623-9.
63. Gonsalkorale WM, Toner BB, Whorwell PJ,. Cognitive change in patients undergoing hypnotherapy for irritable bowel syndrome. J Psychosom Res 2004; 56: 271-8.
64. Lea R, Houghton LA, Calvert EL, et al,. Gut-focused hypnotherapy normalizes disordered rectal sensitivity in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 635-42.
65. Berrigan LP, Kurtz RM, Stabile JP, Strube MJ,. Durability of "posthypnotic suggestions" as a function of type of suggestion and trance depth. Int J Clin Exp Hypn 1991; 39: 24-38.
66. Trussell JE, Kurtz RM, Strube MJ,. Durability of posthypnotic suggestions: type of suggestion and difficulty level. Am J Clin Hypn 1996; 39: 37-47.
67. Bonaz BL, Bernstein CN,. Brain-gut interactions in inflammatory bowel disease. Gastroenterology 2013; 144: 36-49.
68. Lowen MB, Mayer EA, Sjoberg M, et al,. Effect of hypnotherapy and educational intervention on brain response to visceral stimulus in the irritable bowel syndrome. Aliment Pharmacol Ther 2013; 37: 1184-97.
69. Pallis AG, Mouzas IA, Vlachonikolis IG,. The inflammatory bowel disease questionnaire: a review of its national validation studies. Inflamm Bowel Dis 2004; 10: 261-9.
70. Huaman JW, Casellas F, Borruel N, et al,. Cutoff values of the Inflammatory Bowel Disease Questionnaire to predict a normal health related quality of life. J Crohns Colitis 2010; 4: 637-41.
71. Baars JE, Nuij VJ, Oldenburg B, Kuipers EJ, van der Woude CJ,. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis 2012; 18: 1634-40.
72. Dave M, Loftus EV Jr,. Mucosal healing in inflammatory bowel disease-a true paradigm of success? Gastroenterol Hepatol 2012; 8: 29-38.
73. Sexton K, Bernstein MT, Walker JR, et al,. Perceived Stress Is Related to Symptom Burden, but Not Intestinal Inflammation, in Inflammatory Bowel Disease. Digestive Diseases Week, Orlando, FL, 2013.